Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 11, 2022

SELL
$2.02 - $2.9 $2 - $2
-1 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$1.95 - $2.85 $1 - $2
1 New
1 $1,000

Others Institutions Holding NCNA

# of Institutions
1
Shares Held
3.33M
Call Options Held
0
Put Options Held
0

About NuCana plc


  • Ticker NCNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,196,000
  • Market Cap $63.2M
  • Description
  • NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients ...
More about NCNA
Track This Portfolio

Track Gerber Kawasaki Wealth & Investment Management Portfolio

Follow Gerber Kawasaki Wealth & Investment Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gerber Kawasaki Wealth & Investment Management, based on Form 13F filings with the SEC.

News

Stay updated on Gerber Kawasaki Wealth & Investment Management with notifications on news.